Vaxart (OTCMKTS:VXRT) Stock Passes Above 50-Day Moving Average – Time to Sell?

Shares of Vaxart, Inc. (OTCMKTS:VXRT) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.68 and traded as high as $0.76. Vaxart shares last traded at $0.7399, with a volume of 333,049 shares.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Vaxart to a “buy” rating in a research note on Friday, January 23rd.

Vaxart Stock Up 0.2%

The firm has a market cap of $178.62 million, a P/E ratio of 12.33 and a beta of 1.31. The company has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.52.

Vaxart (OTCMKTS:VXRT) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.32. The firm had revenue of $104.24 million during the quarter, compared to analyst estimates of $35.95 million. Vaxart had a return on equity of 33.83% and a net margin of 6.88%.

Hedge Funds Weigh In On Vaxart

A number of hedge funds have recently made changes to their positions in VXRT. Marshall Wace LLP bought a new position in shares of Vaxart in the second quarter worth about $794,000. Jones Financial Companies Lllp boosted its stake in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Vaxart in the first quarter worth about $31,000. Creative Planning bought a new position in shares of Vaxart in the second quarter worth about $33,000. Finally, Invesco Ltd. boosted its stake in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 70,568 shares during the period. Institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.